

Lupin protein: A Clean Food revolution

AGM and Investor Presentation | November 2024

ASX: WOA

FRA: 2WO



Disclaimer

This presentation has been prepared by Wide Open Agriculture Limited (ASX: WOA) (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

This presentation is authorised for release by the Board of Directors



The Opportunity

The Australian-based supplier of premium lupin products for global human consumption

Lupins, a Clean Food source of premium plant-based protein:

- Nutritious
- Smooth Taste
- Sustainable

Positioned to capture a share of the fast-growing US\$15bn¹ plant protein market



2024: A Year of Transition



Ø Our Company:

Solely focused on plant proteins

Disposal of DCF business completed



Ø Our Team:

Board refreshed

Core technical and leadership team retained



Ø Our Production:

Stage one scale up facility in place; working to optimise the facility



Ø Our Sales:

Developing sales pipeline; forging partnerships with global food businesses

Seed with the highest protein & fibre content Highest Fibre Lowest Low oils Highest Protein Chickpea Lentil Fava Pea Lupin

Lupins: a better source of nutrition



Nutrition:

- All essential amino acids
- Excellent protein digestibility
- Whole of seed utilisation



Dietary:

- Suitable for gluten and lactose free diets
- Low GI, Low carb, Keto friendly



Health benefits can include:

- Appetite suppression
- Lowering blood pressure and cholesterol
- Improved blood glucose control

Creating Value – Building IP around Lupin for Humans



WOA has a strategic lupin IP portfolio

8 patent families across multiple geographies

- IP developed by Curtin University
- Acquisition of IP with German facility
- Product Formulations
- Manufacturing Process from CSIRO

WOA: THE Lupin Company



Lupin Fibre



Lupin Flour



Lupin Oil



Lupin Protein



Gamma Conglutin

Lupin protein: Sustainable competitive advantage



High functioning ingredient that excels where colour, texture and taste are critical



Better tasting than pea, better environmentally than soy



Can lower the cost-in-use for food manufacturers compared to other protein sources





Lupins: better for the planet



The food system contributes 34% of global emissions¹



Lupins reduce on farm CO₂ emissions by over 50%²



Reduces the need for synthetic nitrogen fertilisers while improving yields



Works in marginal soils; require less water than meat, soy, almond & pea proteins

Diets are Changing

Customers open to plant based

62% of European consumers identify as 'open omnivores' and 'flexitarians', ready and willing to explore plant-based foods1

APAC a key source of growth

- APAC market size estimated at US\$4.4bn in 2024²
- China the largest market share in the region²



Continued strong market growth

- US\$15bn market, growing at
- Market will double in 10 years

Lupin For Improved Health


Study in Queensland showed 29% improvement in aged care nutritional status when lupin was consumed⁴

- (1) https://proveg.org/article/how-your-business-can-engage-more-with-open-omnivores/
 (2) https://www.mordorintelligence.com/industry-reports/asia-pacific-plant-protein-ingredients-
- Alternative Protein Market Size, Share & Growth Report 2030
- Unique nutritional flour improves aged care residents' health in Queensland program ABC News



Building the Sales Pipeline

18 – 24 month Product R&D Cycle




What are we doing to convert the pipeline?

- **Ø** Education & awareness
- **Ø** Understanding specific needs
- Tailoring Proteins to meet requirements
- Product demonstrations & samples to customers
- Providing technical support

Ø

- Providing cost-benefit analysis
 - Working on co-marketing opportunities



Production Pathway to Scaled Output



R&D Facility

Operational pilot scale facility used for R&D



R&D Facility

5-10tpa



German Facility

Stage one commercial production in place; pathway to larger scale facility



Commercial Production


500 -1,000tpa




Future expansion

L Com

Large Commercial Production




Lupin Protein Path to Market



- Pilot scale production and R&D Facility (10tpa)
 - First orders received from pilot plant
 - R&D: Dairy, baking, supplement & meat
 - Stage One: Production Facility (Germany)
 Stage Two Scale up: optimise process flow

Stage Two: Business case for by products

Stage Two: Feasibility study, secure channel partners





Capital Structure & Team

Current Capital Structure	WOA
Last Price ¹	\$0.01
Shares Outstanding	553m
Market Capitalisation	\$5.5m
Cash on Hand²	\$3.4m
Debt Outstanding ³	\$0.5m
Net Tangible Assets	\$3.9m



(2) As at 30 Sept 2024



Matthew Skinner
Chief Executive
Officer
With a Finance and
Management career
spanning Australia, the UK
and the Middle East,
Matthew brings extensive
experience in managing
complex fast changing
business environments.



Yaxi Zhan
Non-Executive Director & Chair
An experienced executive across startups, large-scale mining operations and ASX-listed companies, Yaxi is recognised for her business acumen and efficiency across diverse business and cultural environments.



Anthony Maslin
Non-Executive
Director & Founder
Anthony is an entrepreneur
and social change
visionary, driven by
bringing new meaning and
hope to environmental and
community projects.



Brett Tucker
Non-Executive Director
& Company Secretary
Brett has over 20 years of
experience providing advisory
and compliance services to
ASX-listed companies across
various industries.

⁽³⁾ R&D Loan @ 30 June 2024

Key Takeaways – a 'Clean Food' investment

- Nutritional, dietary and health benefits of lupins are unrivaled
- (2) WOA has a strategic Lupin IP portfolio
- Lupin protein works in a diverse range of applications where performance is critical
- The market for lupin protein is expanding and we are making initial sales now
- $\left(\begin{array}{c}5\end{array}\right)$ Continuing to optimise production
- 6 Close to the growing APAC market, manufacturing in the heart of Europe

What To Expect in 2025



Improved balance sheet; reduced cash burn, R&D tax rebate



Continue to grow with Channel Partners for supply, distribution and sales



Ongoing research into product development and nutritional benefits

